Immunogenicity and safety of revaccination of 23-valent pneumococcal polysaccharide vaccine in people aged 60 years and above.
10.3760/cma.j.cn112338-20221130-01019
- VernacularTitle:60岁及以上老年人再接种23价肺炎球菌多糖疫苗免疫原性及安全性临床研究
- Author:
Qian Li MA
1
;
Min ZHANG
2
;
Li Jun LIU
1
;
Yan ZHOU
3
;
Wei YUAN
4
;
Mei YANG
1
;
Shao Xiang LIU
5
;
Lin Yun LUO
2
;
Hai Ping CHEN
2
;
Yan Hui XIAO
2
;
Qi QI
1
;
Xiao Ming YANG
2
Author Information
1. Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610041, China.
2. China National Biotech Group Company Limited, Beijing 100024, China.
3. Xinjin District Center for Disease Control and Prevention, Chengdu 611430, China.
4. Sichuan Tianfu New District Public Health Center, Chengdu 610213, China.
5. Chengdu Institute of Biological Products Co. Ltd, Sichuan Vaccine Engineering Technology Research Center, Chengdu 610023, China.
- Publication Type:Journal Article
- From:
Chinese Journal of Epidemiology
2023;44(7):1119-1125
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the immunogenicity and safety of revaccination of 23-valent pneumococcal polysaccharide vaccine (PPV23) in elderly people aged ≥60 years. Methods: The elderly aged ≥60 years with 1 dose of PPV23 vaccination were selected as revaccination group and those without history of pneumococcal vaccine immunization were selected as the first vaccination group. One dose of PPV23 was administered to both groups, and the first blood samples were collected before vaccination while the second blood samples were collected on day 28-40 after vaccination. ELISA was used to detect the concentrations of anti-specific serotype Streptococcus pneumoniae podocyte polysaccharide immunoglobulin G, and the safety of the vaccination was evaluated after 30 days. Results: The geometric mean concentration (GMC) of antibody to 23 serotypes before the vaccination (0.73-13.73 μg/ml) was higher in revaccination group than in the first vaccination group (0.39-7.53 μg/ml), the GMC after the vaccination (1.42-31.65 μg/ml) was higher than that before the vaccination (0.73-13.73 μg/ml) in the revaccination group, and the GMC after the vaccination (1.62-43.76 μg/ml) was higher than that before the vaccination (0.39-7.53 μg/ml) in the first vaccination group; the geometric mean growth multiple in revaccination group (2.16-3.60) was lower than that in the first vaccination group (3.86-16.13); The mean 2-fold antibody growth rate was lower in revaccination group (53.68%, 95%CI: 52.30%-55.06%) than in the first vaccination group (93.16%, 95%CI: 92.18%- 94.15%), all differences were significant (P<0.001). After the vaccination, 13 serotypes of GMC were higher in the first vaccination group than in revaccination group (P<0.001), the differences were not significant for 10 serotypes of GMC (P>0.05). The incidence of local adverse reaction was 19.20% and 13.27% in revaccination group and the first vaccination group, respectively (P=0.174). Conclusions: The antibody level in ≥60 years people who received one dose of PPV23 after a 5-year interval was still higher than that in unvaccinated people. The antibody level decreased after 5 years of the first vaccination, and the antibody level could be rapidly increased by one more dose vaccination, but the overall immune response was lower than that of the first vaccination; revaccination with PPV23 has a good safety.
